Drug Trial Radar · NCT00450203
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
Last checked: Nov 20, 2026Latest source record: Dec 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,103
Planned (sponsor's estimate)
Start
Oct 2007
Primary completion
Dec 2017
Study completion Dec 2017
Sponsor
- Lead sponsor
- Professor David CunninghamGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Cancer Research UK; Roche Pharma AG; GlaxoSmithKline
- First posted
- Mar 22, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cisplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, and small molecule tyrosine kinase inhibitors, such as lapatinib, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Lapatinib targets a specific growth receptor, HER-2. Chemotherapy together with bevacizumab or lapatinib, in HER-2 positive tumours, may kill more tumor cells. PURPOSE: This randomized phase II/III trial is studying the side effects and how well giving combination chemotherapy together with bevacizumab works compared with combination chemotherapy alone in treating patients with previously untreated stomach cancer, gastroesophageal junction cancer or lower oesophageal cancer that can be removed by surgery. The feasibility study is studying the safety of adding lapatinib to chemotherapy in patients with HER-2 positive previously untreated stomach cancer, gastroesophageal junction cancer or lower oesophageal cancer that can be removed by surgery. The feasibility study will also assess the feasibility of timely HER-2 testing and estimate the HER-2 positivity rate in this patient population.
Conditions
- Oesophagogastric Cancer
Interventions
bevacizumabBiological
7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.
capecitabineDrug
dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
cisplatinDrug
60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
EpirubicinDrug
50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
adjuvant therapyProcedure
3 cycles of ECX chemotherapy post operatively
conventional surgeryProcedure
Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.
neoadjuvant therapyProcedure
3 cycles of pre-operative ECX chemotherapy.
LapatinibDrug
1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SafetyTime frame: at the end of phase II and phase III
- EfficacyTime frame: end of trial
- Overall survivalTime frame: end of trial
Locations
41 sites in 1 country. Site status is shown where the registry gives one.
Basingstoke and North Hampshire Hospital
Basingstoke, United Kingdom · Recruiting
Birmingham Heartlands Hospital
Birmingham, United Kingdom · Recruiting
Castle Hill Hospital
Cottingham, United Kingdom · Recruiting
University Hospitals Coventry and Warwickshire
Coventry, United Kingdom · Recruiting
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom · Recruiting
St James Hospital
Leeds, United Kingdom · Recruiting
Leicester Royal Infirmary
Leicester, United Kingdom · Recruiting
Norfolk and Norwich University Hospital
Norwich, United Kingdom · Recruiting
Churchill Hospital
Oxford, United Kingdom · Recruiting
Queens Hospital
Romford, United Kingdom · Recruiting
Weston Park
Sheffield, United Kingdom · Recruiting
Great Western Hospital
Swindon, United Kingdom · Recruiting
Musgrove Park Hospital
Taunton, United Kingdom · Recruiting
Royal Bournemouth Hospital
Bournemouth, England, United Kingdom · Recruiting
Bradford Royal Infirmary
Bradford, England, United Kingdom · Active not recruiting
Bristol Haematology and Oncology Centre
Bristol, England, United Kingdom · Recruiting
Addenbrooke's Hospital
Cambridge, England, United Kingdom · Active not recruiting
Cumberland Infirmary
Carlisle, England, United Kingdom · Active not recruiting
Doncaster Royal Infirmary
Doncaster, England, United Kingdom · Recruiting
St. Luke's Cancer Centre at Royal Surrey County Hospital
Guildford, England, United Kingdom · Recruiting
Huddersfield Royal Infirmary
Huddersfield, West Yorks, England, United Kingdom · Recruiting
Leeds Cancer Centre at St. James's University Hospital
Leeds, England, United Kingdom · Recruiting
Lincoln County Hospital
Lincoln, England, United Kingdom · Active not recruiting
Aintree University Hospital
Liverpool, England, United Kingdom · Recruiting
Saint Bartholomew's Hospital
London, England, United Kingdom · Recruiting
St. George's Hospital
London, England, United Kingdom · Active not recruiting
St. Mary's Hospital
London, England, United Kingdom · Active not recruiting
Mid Kent Oncology Centre at Maidstone Hospital
Maidstone, England, United Kingdom · Recruiting
Christie Hospital
Manchester, England, United Kingdom · Recruiting
Clatterbridge Centre for Oncology
Merseyside, England, United Kingdom · Recruiting
Northern Centre for Cancer Treatment at Newcastle General Hospital
Newcastle upon Tyne, England, United Kingdom · Recruiting
Derriford Hospital
Plymouth, England, United Kingdom · Active not recruiting
Dorset Cancer Centre
Poole Dorset, England, United Kingdom · Active not recruiting
Berkshire Cancer Centre at Royal Berkshire Hospital
Reading, England, United Kingdom · Recruiting
Rochdale Infirmary
Rochdale, England, United Kingdom · Active not recruiting
Salisbury District Hospital
Salisbury, England, United Kingdom · Recruiting
Wexham Park Hospital
Slough, Berkshire, England, United Kingdom · Recruiting
Southampton General Hospital
Southampton, England, United Kingdom · Recruiting
Royal Marsden - Surrey
Sutton, England, United Kingdom · Recruiting
Aberdeen Royal Infirmary
Aberdeen, Scotland, United Kingdom · Recruiting
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.